[CH:1]1[C:6]([CH2:7][C@H:8]([NH2:12])[C:9]([OH:11])=[O:10])=[CH:5][C:4]([OH:13])=[C:3]([OH:14])[CH:2]=1.[CH3:15][C@@:16]([NH:29][NH2:30])([C:26]([OH:28])=[O:27])[CH2:17][C:18]1[CH:19]=[CH:20][C:21]([OH:25])=[C:22]([OH:24])[CH:23]=1>C(O)C>[CH:1]1[C:6]([CH2:7][C@H:8]([NH2:12])[C:9]([OH:11])=[O:10])=[CH:5][C:4]([OH:13])=[C:3]([OH:14])[CH:2]=1.[CH3:15][C@@:16]([NH:29][NH2:30])([C:26]([OH:28])=[O:27])[CH2:17][C:18]1[CH:19]=[CH:20][C:21]([OH:25])=[C:22]([OH:24])[CH:23]=1The formulations in Table 7, containing 200 mg levodopa and 50 mg carbidopa, were prepared as follows. Drug granulate: a solution of 0.75% w/v Klucel LF in ethanol was used as a binding solution for a mixture of 4:1 levodopa:carbidopa. The granulation was carried out in a Zanchetta Rotolab one pot granulator. The granulate was either dried under vacuum in the granulator or air dried at room temperature protected from light. The final composition of the granulate was levodopa 80.5%, Carbidopa 19.9%, Klucel LF 0.6%. A drug granulate containing levodopa was prepared by the same method. Final composition: 99.4% levodopa, 0.6% Klucel LF.